William H Doub
Overview
Explore the profile of William H Doub including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doub W, Suman J, Copley M, Goodey A, Hosseini S, Mitchell J
AAPS PharmSciTech
. 2023 Oct;
24(7):208.
PMID: 37817001
Although nasal inhalation products are becoming more and more important for the delivery of medicines, characterization of these products for quality control and assessment of bioequivalence is complicated. Most of...
2.
Mohan M, Lee S, Guo C, Peri S, Doub W
AAPS PharmSciTech
. 2016 Sep;
18(5):1585-1594.
PMID: 27624069
The full-resolution next generation impactor (NGI) and three abbreviated impactor systems were used to obtain the apparent aerodynamic particle size distribution (APSD) and other quality measures for marketed dry powder...
3.
Doub W, Shah V, Limb S, Guo C, Liu X, Ngo D
J Pharm Sci
. 2014 Sep;
103(11):3648-3656.
PMID: 25228114
As a result of the Montreal Protocol on Substances that Deplete the Ozone Layer, manufacturers of metered dose inhalers began reformulating their products to use hydrofluoroalkanes (HFAs) as propellants in...
4.
Guo C, Ngo D, Ahadi S, Doub W
AAPS PharmSciTech
. 2013 Jun;
14(3):1004-11.
PMID: 23780781
Abbreviated impactors have been developed recently to allow more rapid evaluation of inhalation products as alternates to the eight-stage Andersen Cascade Impactor (ACI) which has been widely used in the...
5.
Doub W, Adams W, Wokovich A, Black J, Shen M, Buhse L
Pharm Res
. 2012 Jul;
29(11):3122-30.
PMID: 22752252
Purpose: To determine if cascade impactor (CI) measurement of drug in small particles from aqueous nasal sprays, described in FDA's 2003 draft Nasal Bioavailability/Bioequivalence Guidance, can be optimized to reduce...
6.
Adams W, Lee S, Plourde R, Lionberger R, Bertha C, Doub W, et al.
AAPS J
. 2012 Apr;
14(3):400-9.
PMID: 22476943
The study examined the sensitivity of DPI in vitro performance to formulation and device changes. Rotahaler/Rotacaps was selected as the reference DPI drug product, and Aerolizer was selected as the...
7.
Liu X, Doub W, Guo C
Int J Pharm
. 2011 Dec;
423(2):235-9.
PMID: 22183132
Droplet velocity is an important parameter which can significantly influence inhalation drug delivery performance. Together with the droplet size, this parameter determines the efficiency of the deposition of MDI products...
8.
Wokovich A, Shen M, Doub W, Machado S, Buhse L
Drug Dev Ind Pharm
. 2011 Mar;
37(10):1217-24.
PMID: 21438703
Background: Complaints from healthcare providers that the adhesive on the Daytrana™ methylphenidate transdermal drug delivery system (TDDS) adhered to the release liner to such an extent that the release liner...
9.
Liu X, Doub W, Guo C
AAPS PharmSciTech
. 2011 Feb;
12(1):337-43.
PMID: 21286880
Droplet velocity is an important parameter that can be used to characterize nasal spray products. In this study, a phase-Doppler anemometry (PDA) system was used to measure the droplet velocities...
10.
Gao Z, Ahadi S, Moore T, Doub W, Westenberger B, Buhse L
J Pharm Sci
. 2010 Aug;
100(3):1093-101.
PMID: 20803604
Dissolution testing of pharmaceutical products is an important technique used extensively for both product development and quality control, but there are many variables that can affect dissolution results. In this...